Status:
COMPLETED
Differentiation Induction in Acute Myelogenous Leukemia
Lead Sponsor:
University of Bergen
Conditions:
Acute Myelogenous Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Hypothesis: Differentiation induction therapy in acute myelogenous leukemia (AML) can be used to achieve disease control and stabilize peripheral blood counts in patients with acute myelogenous leukem...
Detailed Description
Patients to be included: 1. Elderly patients above 60 years of age with newly diagnosed acute myelogenous leukemia (AML) who cannot receive conventional intensive chemotherapy. 2. Adult patients of a...
Eligibility Criteria
Inclusion
- Recently diagnosed acute myelogenous leukemia (AML)
- Patients above 60 years of age
- Patients who cannot receive conventional chemotherapy
- Patients with relapsed or refractory AML independent of age
Exclusion
- Chronic myelogenous leukemia in blast phase
- Intolerance to the study drugs
- Serious liver disease
- No informed consent
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00175812
Start Date
November 1 2004
End Date
November 1 2009
Last Update
June 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haukeland University Hospital, University of Bergen
Bergen, Norway, N-5021